Liver Function's impact on drug breakdown under microscope
NCT ID NCT04271488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how mild and moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 people with stable liver impairment to healthy volunteers matched by age, weight, race, and gender. The goal is to understand how the liver processes the drug, which helps guide safe dosing for patients with liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eisai Trial Site #1
RECRUITINGMintato-ku, Tokyo, Japan
-
Eisai Trial Site #2
RECRUITINGYuhu, Oita Prefecture, Japan
-
Eisai Trial Site #3
RECRUITINGBukyo-ku, Tokyo, Japan
-
Eisai Trial Site #4
TERMINATEDKurume, Fukuoka, Japan
-
Eisai Trial Site #5
RECRUITINGKofu, Yamanashi, Japan
-
Eisai Trial Site #6
RECRUITINGHakata, Fukuoka, Japan
-
Eisai Trial Site #7
RECRUITINGKyoto, Japan
-
Eisai Trial Site #8
RECRUITINGShinjuku-ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug